Private equity firm CX Partners is likely to reap a return of 3X (three times) over its four-year-old investment in diagnostics major Thyrocare Technologies. According to people in the know, the $500-million fund will dilute 25 per cent of its 27 per cent stake in Thyrocare Technologies, which is likely to launch its initial public offer (IPO) in February 2015.
Hey, check out all the engineering jobs. Post your resume today!
